The difference in estimated median progression-free survival was greater in the ER-positive/PR-negative/HER2-negative tumor than in the ER-positive/PR-positive/HER2-negative tumor when CDK4/6 inhibitor was used for patients with advanced breast cancer (9.2 months vs 7.9 months) [38]. Here, ERBB2 is linked to neoplasm.